← Back to Search

Gallium Ga 68 PSMA-R2 for Prostate Adenocarcinoma

Phase 2
Waitlist Available
Research Sponsored by Andrei Iagaru
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year post-scan follow-up
Awards & highlights

Study Summary

This trial studies PET/MRI scans to diagnose prostate cancer and how far it has spread.

Eligible Conditions
  • Prostate Adenocarcinoma
  • Prostate-Specific Antigen
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year post-scan follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year post-scan follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Lesions Detected by Investigational Imaging Agent
Secondary outcome measures
Number of Detected Lesions Confirmed to be Malignant for Each Imaging Method

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)Experimental Treatment2 Interventions
Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
Group II: Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2Experimental Treatment2 Interventions
Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gallium Ga 68 DOTA-NeoBOMB1
2020
Completed Phase 2
~30
Gallium Ga 68 PSMA-R2
2020
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Andrei IagaruLead Sponsor
15 Previous Clinical Trials
569 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Andrei Iagaru 2020. "Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03698370.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top